<?xml version="1.0" encoding="UTF-8"?>
<p id="p0520">The mechanism of action of CQ for anti-malarial treatment is not entirely clear, but the interference with the digestion of haemoglobin by the parasite has been suggested.
 <xref rid="b1220" ref-type="bibr">
  <sup>244</sup>
 </xref> HCQ has a similar mechanism, however, in regard to SARS-CoV-2, clinical trials showed it to be safer.
 <xref rid="b1225" ref-type="bibr">245</xref>, 
 <xref rid="b1230" ref-type="bibr">246</xref>, 
 <xref rid="b1235" ref-type="bibr">247</xref> Therefore, HCQ, rather than CQ, is used against SARS-CoV-2. Recent studies report antiviral activity of CQ and HCQ as they impair viral entry and release in different 
 <italic>in-vitro</italic> and 
 <italic>in-vivo</italic> models.
 <xref rid="b1215" ref-type="bibr">243</xref>, 
 <xref rid="b1240" ref-type="bibr">248</xref> A factor that can also justify antiviral mechanisms is the aminoquinoline bioaccumulation in the tissues, as defended by Patil, Singhal &amp; Masand.
 <xref rid="b1210" ref-type="bibr">
  <sup>242</sup>
 </xref>
</p>
